Catastrophic health expenditures for colorectal cancer care: A retrospective analysis of the first private comprehensive cancer center in Lagos, Nigeria.

IF 2.7 3区医学 Q1 SURGERY American journal of surgery Pub Date : 2024-12-10 DOI:10.1016/j.amjsurg.2024.116140

Frankie I Uwechue, Matt Caputo, Norah N Zaza, Toluwanimi Aduloju, Egide Abahuje, Zainab Adegbite, Chinenye Iwuji, Chukwumere Nwogu, Bindiya Sadarangani, Kristina Diaz, Juliet S Lumati

{"title":"Catastrophic health expenditures for colorectal cancer care: A retrospective analysis of the first private comprehensive cancer center in Lagos, Nigeria.","authors":"Frankie I Uwechue, Matt Caputo, Norah N Zaza, Toluwanimi Aduloju, Egide Abahuje, Zainab Adegbite, Chinenye Iwuji, Chukwumere Nwogu, Bindiya Sadarangani, Kristina Diaz, Juliet S Lumati","doi":"10.1016/j.amjsurg.2024.116140","DOIUrl":null,"url":null,"abstract":"Background: Nearly a billion people worldwide risk Financial Catastrophe (FC) due to Out-of-Pocket (OOP) health expenditures. With Low-and-Middle-Income Countries (LMICs) disproportionately impacted, and the global burden of colorectal cancer (CRC) expected to increase 60 % by 2030, Nigeria is of interest. This study aims to evaluate the cost of treating CRC at Nigeria's first private cancer center.Methods: The center's cancer registry was queried for CRC diagnosed between 2013 and 2023. Two research assistants in Lagos abstracted treatment costs (adjusted to 2023 USD), demographics and clinical characteristics. FC was defined as OOP >20 % of Nigeria's 2023 per-capita GDP ($467).Results: 92 patients (colon (n = 70), rectum (n = 22), 66 % stage 4) were included. Average chemotherapy cost $7,678, procedure cost $1157. Average total cost for multi-therapy, $34,983. All treated patients risked FC. The greatest cost-contributors were chemotherapy (30 %) and other drugs (21 %). Procedures cost 3 %.Conclusion: CRC treatment increases the risk of FC for nearly all patients. Risk-protection through insurance or financial navigation may be of benefit, and future studies should investigate the impact of these interventions on FC risk.","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":" ","pages":"116140"},"PeriodicalIF":2.7000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amjsurg.2024.116140","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Nearly a billion people worldwide risk Financial Catastrophe (FC) due to Out-of-Pocket (OOP) health expenditures. With Low-and-Middle-Income Countries (LMICs) disproportionately impacted, and the global burden of colorectal cancer (CRC) expected to increase 60 % by 2030, Nigeria is of interest. This study aims to evaluate the cost of treating CRC at Nigeria's first private cancer center.

Methods: The center's cancer registry was queried for CRC diagnosed between 2013 and 2023. Two research assistants in Lagos abstracted treatment costs (adjusted to 2023 USD), demographics and clinical characteristics. FC was defined as OOP >20 % of Nigeria's 2023 per-capita GDP ($467).

Results: 92 patients (colon (n = 70), rectum (n = 22), 66 % stage 4) were included. Average chemotherapy cost $7,678, procedure cost $1157. Average total cost for multi-therapy, $34,983. All treated patients risked FC. The greatest cost-contributors were chemotherapy (30 %) and other drugs (21 %). Procedures cost 3 %.

Conclusion: CRC treatment increases the risk of FC for nearly all patients. Risk-protection through insurance or financial navigation may be of benefit, and future studies should investigate the impact of these interventions on FC risk.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

结直肠癌护理的灾难性卫生支出：对尼日利亚拉各斯第一家私营综合癌症中心的回顾性分析。

背景：全球近10亿人因自费医疗支出而面临金融灾难（FC）风险。由于低收入和中等收入国家（LMICs）受到了不成比例的影响，全球结直肠癌（CRC）负担预计到2030年将增加60%，尼日利亚引起了人们的兴趣。本研究旨在评估尼日利亚第一家私人癌症中心治疗结直肠癌的成本。方法：查询该中心癌症登记处2013年至2023年诊断的结直肠癌。拉各斯的两名研究助理提取了治疗费用（调整为2023美元）、人口统计学和临床特征。FC被定义为2023年尼日利亚人均GDP（467美元）的20%。结果：纳入92例患者（结肠70例，直肠22例，4期66%）。平均化疗费用为7678美元，手术费用为1157美元。综合治疗的平均总费用为34,983美元。所有接受治疗的患者都有FC风险。最大的费用来源是化疗（30%）和其他药物（21%）。手术费用为3%。结论：CRC治疗几乎增加了所有患者发生FC的风险。通过保险或金融导航进行风险保护可能是有益的，未来的研究应调查这些干预措施对FC风险的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American journal of surgery 医学-外科

CiteScore

5.00

自引率

6.70%

发文量

570

审稿时长

56 days

期刊介绍： The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.